We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents with the potential to reach the market this year for cystic fibrosis, congenital adrenal hyperplasia, and bladder cancer.
- Other significant treatments expected in the next few years, including gene therapies and biosimilars in the pipeline.
- Updated vaccination recommendations for respiratory syncytial virus (RSV) and coronavirus disease 2019 (COVID-19), and an update on a recently approved treatment for early Alzheimer’s disease.
- A spotlight on the FDA rare disease drug and biologic development programs.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
You may also be interested in:
Q3 2024 CarelonRx DrugInsights
Our Evidence-Based Formulary Development Process
